Jump to content

User:XyZAn/sandbox/JNJ add

From Wikipedia, the free encyclopedia

History

[edit]

Johnson & Johnson operates over 260 companies, in what is termed, the "the Johnson & Johnson family of companies".[1] The company operates is three broad divisions; Consumer Healthcare, Medical Devices and Pharmaceuticals.

Johnson & Johnson Family of Companies
Consumer Healthcare[2] Medical Devices[3] Pharmaceuticals[4]
Baby Care
Skin & Hair Care
Wound Care and Topicals
Oral Health Care
Women’s Health
Over-The-Counter Medicines
Nutritionals
Advanced Sterilization Products
Animas Corporation
Biosense Webster
DePuy Synthes Companies of Johnson & Johnson
Ethicon, Inc.
Janssen Diagnostics BVBA
Johnson & Johnson Vision Care, Inc.
LifeScan, Inc.
Mentor
Janssen
Janssen R&D LLC
Janssen Healthcare Innovation
Janssen Pharmaceuticals Inc
Janssen Diagnostics
Janssen Therapeutics
Janssen Scientific Affairs

Foundation & Early history

[edit]
Robert Wood Johnson

Inspired by a speech by antiseptic advocate Joseph Lister, Robert Wood Johnson joined his brothers James Wood Johnson and Edward Mead Johnson to create a line of ready-to-use surgical dressings in 1885. The company produced its first products in 1886 and incorporated in 1887.

Robert Wood Johnson served as the first president of the company. He worked to improve sanitation practices in the nineteenth century, and lent his name to a hospital in New Brunswick, New Jersey. Upon his death in 1910, he was succeeded in the presidency by his brother James Wood Johnson until 1932, and then by his son, Robert Wood Johnson II.

Robert Wood Johnson's granddaughter, Mary Lea Johnson Richards, was the first baby to appear on a Johnson & Johnson baby powder label.[5][6][7] His great-grandson, Jamie Johnson, made a documentary called Born Rich about the experience of growing up as the heir to one of the world's greatest fortunes.

1959: McNeil Consumer Healthcare

[edit]

McNeil Consumer Healthcare was founded on March 16, 1879 by 23-year-old Robert McNeil. In 1904, one of McNeil's sons, Robert Lincoln McNeil, became part of the company and together they created McNeil Laboratories in 1933. The company focused on direct marketing of prescription drugs to hospitals, pharmacists, and doctors. Development of acetaminophen began under the leadership of Robert L. McNeil, Jr., who later served as the firm's chairman.[8] In 1959, Johnson & Johnson acquired McNeil Laboratories and a year later the company was able to sell Tylenol for the first time ever, without a prescription. In 1977, two subsidiary companies were created; McNeil medicals products and McNeil Consumer Products Company (also known as McNeil Consumer Healthcare). The focus of McNeil medicals products is to market prescription drugs. In 1993 McNeil medicals products merged with the Ortho Pharmaceutical to form Ortho-McNeil Pharmaceutical. In 2001 McNeil Consumer Healthcare changed its name to McNeil Consumer & Specialty medicals products. However, it was later changed to "McNeil Consumer Healthcare". The company markets over-the-counter and prescription medicals products including complete lines of Tylenol and Motrin IB (ibuprofen) products for adults and children.

1959: Cilag

[edit]

In 1933, Swiss chemist Bernhard Joos set up a small research laboratory in Schaffhausen, Switzerland. This set the basis for the founding of Chemische Industrie-Labor AG (Chemical Industry Laboratory AG or Cilag) on 12 May 1936. In 1959, Cilag joined the Johnson & Johnson family of companies. In the early nineties the marketing organizations of Cilag and Janssen Pharmaceutica were joined to form Janssen-Cilag. The non-marketing activities of both companies still operate under their original name. Cilag continues to have operations under the Cilag name in Switzerland, ranging from research and development through manufacturing and international services. In August 2014 Cilag acquired Covagen a biopharmaceutical company which specialises in the development of multi-specific protein based therapeutics. As part of the acquisition Cilag wll gain access to Covagen’s lead drug candidate, COVA 322, a bi-specific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is in a Phase Ib study for psoriasis.[9]

1961: Janssen Pharmaceutica

[edit]

Janssen Pharmaceuticals can be traced back to 1933. In 1933 Constant Janssen, the father of Paul Janssen, acquired the right to distribute the pharmaceutical products of Richter, a Hungarian pharmaceutical company, for Belgium, the Netherlands and Belgian Congo. On 23 October 1934, he founded the N.V. Produkten Richter in Turnhout. After the Second World war, the name for the company products was changed to Eupharma, although the company name Richter would remain until 1956.[10]

Paul Janssen founded his own research laboratory in 1953 on the third floor of the building in the Statiestraat, still within the Richter-Eurpharma company of his father. On 5 April 1956, the name of the company was changed to NV Laboratoria Pharmaceutica C. Janssen (named after Constant Janssen). On 2 May 1958, the research department in Beerse became a separate legal entity, the N.V. Research Laboratorium C. Janssen. On 24 October 1961, the company was acquired by the American corporation Johnson & Johnson. On 10 February 1964, the name was changed to Janssen Pharmaceutica N.V. Between 1990 and 2004, Janssen Pharmaceuticals expanded worldwide, with the company grew in size to approximately 28000 employees worldwide. In 1999, clinical research and non-clinical development become a global organization within Johnson & Johnson. In 2001, part of the research activities was transferred to the United States with the reorganization of research activities in the Johnson & Johnson Pharmaceutical Research and Development organization. The research activities of the Janssen Research Foundation and the R.W. Johnson Pharmaceutical Research Institute were merged into the new global research organization. On 27 October 2004, the Paul Janssen Research Center, for discovery research, was inaugurated.

In August 2013, the company acquired Aragon Pharmaceuticals, Inc.. In November 2014, the company acquired Alios BioPharma, Inc. for $1.75 billion. As a result of the purchase, Alios was incorporated into the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson.[11] In March 2015, Janssen licensed Tipofarnib (a farnesyl transferase inhibitor) to Kura Oncology who will assume sole responsibility for developing and commericalisaing the anti-cancer drug.[12] Later in the same month the company announced that Galapagos Pharma and regained the rights to the anti-inflammatory drug candidate GLPG1690 as well as two other compounds including GLPG1205 (a first-in-class inhibitor of GPR84).[13] Finally, in March, the company acquired XO1 Limited [14] In November 2015, the company acquired Novira Therapeutics, Inc., gaining the lead candidate, NVR 3-778.[15]

1998:DePuy

[edit]

DePuy was acquired by J&J in 1998, rolling it into the Johnson & Johnson Medical Devices group. On June 14, 2012, Johnson and Johnson completed the acquisition of Synthes for $19.7 billion,[16] which was then integrated with the DePuy franchise to establish the DePuy Synthes Companies of Johnson & Johnson which includes; Codman & Shurteff, Inc., DePuy Mitek, Inc., DePuy Orthopaedics, Inc. and DePuy Spine, Inc.

1999: Janssen Biotech, Inc.

[edit]

Janssen Biotech, Inc., formerly known as Centocor Biotech, Inc., is a biotechnology company that was founded in Philadelphia in 1979. In 1982 Centocor transitioned into a publicly traded company. In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson. Since the acquisition, Janssen Biotech increased its annual sales from $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million. In 2008, Centocor, Inc. and Ortho Biotech Inc. merged to form Centocor Ortho Biotech Inc. In June 2010 Centocor Ortho Biotech acquired RespiVert, a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.[17] In June 2011 Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity. In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours. This could net MacroGenics up to $700 million.[18] In January 2015, the company announced it will utilise Isis Pharmaceuticals' RNA-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract, with the partnership potentially generating up to $835 million for Isis.[19]

Ethicon, Inc

[edit]

In 1915, George F. Merson opened a facility in Edinburgh for the manufacturing, packaging and sterilising of catgut, silk and nylon sutures. Johnson & Johnson acquired Mr. Merson’s company in 1947, and this was renamed Ethicon Suture Laboratories.[20] In 1953 this became Ethicon Inc.[21] In 1992, Ethicon was restructured, and Ethicon Endo-Surgery, Inc. became a separate corporate entity. During the 1990s, Ethicon diversified into new and advanced products and technologies and formed four different companies under the Ethicon umbrella, each of which specialize in different products. In 2008 J&J announced it would acquire Mentor Corporation for $1 billion and merge its operations into Ethicon.[22]

Ethicon Endo-Surgery, Inc.

[edit]

Ethicon Endo-Surgery was part of Ethicon Inc. until 1992, when it became a separate corporate entity under the J&J umbrella.

2010: Crucell

[edit]

In October 2010 J&J acquired Crucell for $2.4 billion.[23]

  1. ^ "J&J Company Structure - Johnson & Johnson".
  2. ^ "Consumer Health Care".
  3. ^ "Medical Devices".
  4. ^ "Pharmaceutical Companies - Johnson & Johnson".
  5. ^ Horner, Shirley (February 15, 1987). "About Books". The New York Times. Retrieved May 7, 2010.
  6. ^ Conniff, Richard. The Natural History of the Rich: A Field Guide. W. W. Norton. p. 126.
  7. ^ "Crazier then You and Me". New York Magazine. February 23, 1987: 129. {{cite journal}}: Cite journal requires |journal= (help)
  8. ^ Singer, Natasha (June 3, 2010). "Robert L. McNeil Jr., Chemist Who Introduced Tylenol, Dies at 94". The New York Times. Retrieved June 4, 2010.
  9. ^ "Janssen Affiliate Cilag Acquires Covagen". GEN.
  10. ^ Lopez-Munoz, Francisco; Alamo, Cecilio (2009). "The Consolidation of Neuroleptic Therapy: Janssen, the Discovery of Haloperidol and Its Introduction into Clinical Practice". Brain Research Bulletin. 79: 130–141. doi:10.1016/j.brainresbull.2009.01.005. PMID 19186209.
  11. ^ "Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition". Janssen.
  12. ^ "GEN - News Highlights:Kura Oncology Licenses Janssen's Tipofarnib in Cancer". GEN.
  13. ^ "GEN - News Highlights:Galapagos Regains Rights to GLPG1690 from Janssen". GEN.
  14. ^ "Janssen Acquires XO1 Limited". Janssen.
  15. ^ "Johnson & Johnson Announces Agreement To Acquire Novira Therapeutics, Inc". Janssen.
  16. ^ "Johnson & Johnson Announces Completion of Synthes Acquisition".
  17. ^ http://www.infogrok.com/index.php/pharmaceutical/centocor-ortho-biotech-acquires-respivert.html
  18. ^ "Janssen Joins MacroGenics in Up-to-$700M Cancer Collaboration". GEN.
  19. ^ "Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement". GEN.
  20. ^ "ETHICON History". www.ethiconproducts.co.uk. Retrieved 25 January 2016.
  21. ^ "A history of advancing surgery". www.ethicon.com. Ethicon U.S., LLC. Retrieved 25 January 2016.
  22. ^ "Johnson & Johnson Announces Definitive Agreement to Acquire Mentor Corporation".
  23. ^ Eva von Schaper and Ellen Gibson (6 October 2010). "J&J, Crucell Reach Agreement on $2.4 Billion Takeover". Bloomberg.com.